Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

Yasuhiro Oki, Barbara Pro, Luis E. Fayad, Jorge Romaguera, Felipe Samaniego, Fredrick Hagemeister, Sattva Neelapu, Peter McLaughlin, Andre Goy, Anas Younes*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Fingerprint Dive into the research topics of 'Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences